COMPANY

Synthekine

HQ: Menlo Park, CA source · synthekine.com ↗

Keywords: oncology metabolic cancer metabolic diseases Non Small Cell Lung Cancer Untreated Advanced NSCLC 1st Line NSCLC Systemic Lupus Erythematosus Lupus Nephritis Systemic Sclerosis CLL/SLL NHL Mantle Cell Lymphoma Follicular Lymphoma Large B-cell Lymphoma Indolent B-Cell Non-Hodgkin Lymphoma Diffuse Large B Cell Lymphoma SYNCAR-001 STK-009 STK-012

Location: Menlo Park, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Raises and deals from press releases

Deal Merck deal · amount not disclosed · announced Feb 26, 2026 Company release ↗
Source quote
- Feb 26, 2026 · Company release ↗
  “MENLO PARK, CA – February 26, 2026 – Synthekine Inc ., an engineered cytokine therapeutics company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada)”
Deal Sanofi deal · $40M upfront · announced Jan 29, 2024 Company release ↗
Source quote
- Jan 29, 2024 · Company release ↗
  “Synthekine to receive $40 million upfront payment and eligible to receive milestones, in addition to tiered royalties on net sales MENLO PARK, CA – Jan. 29, 2024 – Synthekine Inc ., an engineered cytokine therapeutics company, today announced a worldwide collaboration”

From the company’s own releases; this list is partial. All raises and deals

Timeline

Apr 29, 2025 Trial start 1: A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease source ↗
Apr 23, 2023 Trial start Phase 1: Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies source ↗
Jan 25, 2022 Trial start Phase 1/Phase 2: Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers source ↗

Upcoming milestones

2028-04 (ESTIMATED) · 1 · A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease · NCT06544330
Jun 24, 2028 (ESTIMATED) · Phase 1 · Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies · NCT05665062
2029-01 (ESTIMATED) · Phase 1/Phase 2 · Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers · NCT05098132

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT05098132	Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers	Phase 1/Phase 2	Recruiting	Jan 25, 2022	2029-01 (estimated)
NCT06544330	A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease	1	Active, not recruiting	Apr 29, 2025	2028-04 (estimated)
NCT05665062	Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies	Phase 1	Active, not recruiting	Apr 23, 2023	Jun 24, 2028 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of Bain Capital Life Sciences (captured Oct 12, 2026). portfolio page ↗